Economics • Practice • Informatics

Topic

Contrast Agent

ICUS applauds FDA on proposed contrast agent label change

Regulatory News | Wednesday, December 14
The International Contrast Ultrasound Society (ICUS) threw its support behind a proposed FDA label change that would affect the use of Optison, an ultrasound contrast agent marketed by GE Healthcare for use in contrast-enhanced ultrasound procedures.
 

FDA decides to take warning label off ultrasound contrast

Regulatory News | Friday, October 28
The International Contrast Ultrasound Society (ICUS) has applauded the FDA’s decision to modify the U.S. product label for Definity Injectable Suspension, an ultrasound contrast agent.